SG11202104344RA - An aurora a kinase inhibitor for use in the treatment of neuroblastoma - Google Patents
An aurora a kinase inhibitor for use in the treatment of neuroblastomaInfo
- Publication number
- SG11202104344RA SG11202104344RA SG11202104344RA SG11202104344RA SG11202104344RA SG 11202104344R A SG11202104344R A SG 11202104344RA SG 11202104344R A SG11202104344R A SG 11202104344RA SG 11202104344R A SG11202104344R A SG 11202104344RA SG 11202104344R A SG11202104344R A SG 11202104344RA
- Authority
- SG
- Singapore
- Prior art keywords
- aurora
- neuroblastoma
- treatment
- kinase inhibitor
- kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773367P | 2018-11-30 | 2018-11-30 | |
| PCT/US2019/062718 WO2020112514A1 (en) | 2018-11-30 | 2019-11-22 | An aurora a kinase inhibitor for use in the treatment of neuroblastoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104344RA true SG11202104344RA (en) | 2021-05-28 |
Family
ID=68916597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104344RA SG11202104344RA (en) | 2018-11-30 | 2019-11-22 | An aurora a kinase inhibitor for use in the treatment of neuroblastoma |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220000855A1 (pt) |
| EP (1) | EP3886855A1 (pt) |
| JP (2) | JP2022508183A (pt) |
| KR (1) | KR20210084555A (pt) |
| CN (1) | CN113038950A (pt) |
| AU (1) | AU2019388843B2 (pt) |
| BR (1) | BR112021006578A2 (pt) |
| CA (1) | CA3121483A1 (pt) |
| EA (1) | EA202191051A1 (pt) |
| IL (1) | IL282270A (pt) |
| MA (1) | MA54290A (pt) |
| MX (1) | MX2021006011A (pt) |
| SG (1) | SG11202104344RA (pt) |
| UA (1) | UA125892C2 (pt) |
| WO (1) | WO2020112514A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI785474B (zh) * | 2020-01-22 | 2022-12-01 | 大陸商北京加科思新藥研發有限公司 | 用作選擇性Aurora A抑制劑的新型雜環化合物 |
| CN117836285A (zh) * | 2021-07-28 | 2024-04-05 | 北京加科思新药研发有限公司 | Aurora a选择性抑制剂的多晶型及其用途 |
| WO2023196887A1 (en) | 2022-04-08 | 2023-10-12 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and aurora a inhibitors |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9576309B2 (en) | 2014-11-12 | 2017-02-21 | Snergy Inc. | Dynamic power sharing system and map view graphical user interface |
| TWI693218B (zh) * | 2014-11-14 | 2020-05-11 | 美商美國禮來大藥廠 | 極光ａ激酶抑制劑 |
-
2019
- 2019-11-22 UA UAA202101953A patent/UA125892C2/uk unknown
- 2019-11-22 KR KR1020217015919A patent/KR20210084555A/ko not_active Application Discontinuation
- 2019-11-22 CA CA3121483A patent/CA3121483A1/en active Pending
- 2019-11-22 EP EP19821387.8A patent/EP3886855A1/en not_active Withdrawn
- 2019-11-22 EA EA202191051A patent/EA202191051A1/ru unknown
- 2019-11-22 JP JP2021529009A patent/JP2022508183A/ja active Pending
- 2019-11-22 US US17/295,721 patent/US20220000855A1/en active Pending
- 2019-11-22 WO PCT/US2019/062718 patent/WO2020112514A1/en active Application Filing
- 2019-11-22 SG SG11202104344RA patent/SG11202104344RA/en unknown
- 2019-11-22 MX MX2021006011A patent/MX2021006011A/es unknown
- 2019-11-22 BR BR112021006578-4A patent/BR112021006578A2/pt unknown
- 2019-11-22 CN CN201980077760.3A patent/CN113038950A/zh active Pending
- 2019-11-22 AU AU2019388843A patent/AU2019388843B2/en not_active Ceased
- 2019-11-22 MA MA054290A patent/MA54290A/fr unknown
-
2021
- 2021-04-12 IL IL282270A patent/IL282270A/en unknown
-
2023
- 2023-02-07 JP JP2023016982A patent/JP2023058582A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA3121483A1 (en) | 2020-06-04 |
| MA54290A (fr) | 2022-03-09 |
| MX2021006011A (es) | 2021-09-21 |
| JP2022508183A (ja) | 2022-01-19 |
| US20220000855A1 (en) | 2022-01-06 |
| EP3886855A1 (en) | 2021-10-06 |
| JP2023058582A (ja) | 2023-04-25 |
| AU2019388843A1 (en) | 2021-05-20 |
| KR20210084555A (ko) | 2021-07-07 |
| BR112021006578A2 (pt) | 2021-07-27 |
| CN113038950A (zh) | 2021-06-25 |
| WO2020112514A1 (en) | 2020-06-04 |
| AU2019388843B2 (en) | 2023-03-23 |
| UA125892C2 (uk) | 2022-06-29 |
| IL282270A (en) | 2021-05-31 |
| EA202191051A1 (ru) | 2021-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288231A (en) | An inhibitor of jak1/2 or a pharmaceutical salt derived from it and an inhibitor of pi3k or a pharmaceutical salt derived from it, for use in the treatment of myelofibroblasts. | |
| IL292642A (en) | ras inhibitors | |
| IL292643A (en) | ras inhibitors | |
| IL292644A (en) | ras inhibitors | |
| IL264687B (en) | cdk2/4/6 pyridopyrimidinone inhibitors | |
| IL282270A (en) | An Aurora A kinase inhibitor for use in the treatment of neuroblastoma | |
| IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| EP3804707A4 (en) | KINASE INHIBITORS | |
| EP3681499A4 (en) | CONNECTIONS AS RAS INHIBITORS AND THEIR USE | |
| IL282350A (en) | Bernani-RGMC inhibitors and their use | |
| IL281634A (en) | Diacosocyclobutanylamino-3-hydroxy-picoline modified amide and its use as a CCR6 inhibitor | |
| IL284514A (en) | Halo-allylamine compounds and their use | |
| IL282588A (en) | Heterocyclic kinase inhibitors and their use | |
| ZA202102261B (en) | Spak kinase inhibitors as neuroprotective agents | |
| IL277749A (en) | Palladianolide compounds and their use | |
| EP3564242A4 (en) | CONNECTION FOR THE SELECTIVE INHIBITION OF KINASE AND THEIR USE | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| IL283687A (en) | usp19 inhibitors and their use for therapeutic purposes | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| EP4051270A4 (en) | 4-AMINO-IMODAZOCINOLINE COMPOUNDS AND USES THEREOF | |
| EP3831829A4 (en) | CDK8/19 INHIBITORS | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| EP3684354A4 (en) | XPA INHIBITOR CONNECTIONS AND THEIR USE | |
| IL279000A (en) | Treatment with AGI-134 together with a checkpoint inhibitor for the treatment of solid cancerous tumors |